Drug intelligence / Profile preview

Oryz-Aspergillus Enzyme

Development stage: Preclinical
Lead developer: Biozyme
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Oral

Overview

Oryz-Aspergillus Enzyme is an enzyme preparation derived from *Oryza* (rice) and *Aspergillus* species. It is primarily investigated as a component in combination tablets, often with pancreatin, to aid in digestion and improve nutritional status. Clinical trials have explored its efficacy in conditions such as cirrhosis with malnutrition, dyspepsia after cholecystectomy, and postprandial distress syndrome. It is administered orally.

Beyond the preview

Go deeper on Oryz-Aspergillus Enzyme.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oryz-Aspergillus Enzyme.

Explore the full profile